American International Group Inc. decreased its holdings in shares of Mylan (NASDAQ:MYL) by 3.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 207,471 shares of the company’s stock after selling 6,397 shares during the quarter. American International Group Inc.’s holdings in Mylan were worth $8,542,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Rational Advisors LLC acquired a new stake in Mylan during the 4th quarter valued at $190,000. First Personal Financial Services lifted its holdings in Mylan by 77.1% during the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after purchasing an additional 2,106 shares during the last quarter. Lombard Odier Asset Management Europe Ltd acquired a new stake in Mylan during the 4th quarter valued at $209,000. Mycio Wealth Partners LLC acquired a new stake in Mylan during the 4th quarter valued at $212,000. Finally, Advisor Partners LLC acquired a new stake in Mylan during the 4th quarter valued at $214,000. 83.66% of the stock is owned by institutional investors and hedge funds.
Several research analysts have weighed in on the company. BidaskClub cut Mylan from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 26th. Susquehanna Bancshares reiterated a “positive” rating and set a $55.00 price objective (up previously from $47.00) on shares of Mylan in a research report on Thursday, January 25th. Morgan Stanley upgraded Mylan from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $39.00 to $50.00 in a research report on Tuesday, March 6th. UBS set a $54.00 price objective on Mylan and gave the stock a “buy” rating in a research report on Thursday, March 1st. Finally, ValuEngine cut Mylan from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $47.02.
Shares of NASDAQ MYL opened at $39.55 on Tuesday. The company has a current ratio of 1.06, a quick ratio of 0.65 and a debt-to-equity ratio of 1.03. Mylan has a 52 week low of $29.39 and a 52 week high of $47.82. The firm has a market capitalization of $20.44 billion, a P/E ratio of 8.67, a P/E/G ratio of 1.29 and a beta of 1.35.
Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, May 9th. The company reported $0.96 EPS for the quarter, missing the Zacks’ consensus estimate of $0.99 by ($0.03). Mylan had a return on equity of 18.56% and a net margin of 6.04%. The company had revenue of $2.68 billion during the quarter, compared to the consensus estimate of $2.74 billion. During the same quarter in the previous year, the business posted $0.93 EPS. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. equities analysts anticipate that Mylan will post 5.36 EPS for the current year.
In related news, Director Robert J. Coury sold 150,000 shares of the firm’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $40.10, for a total value of $6,015,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Anthony Mauro sold 12,257 shares of the firm’s stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $40.35, for a total value of $494,569.95. Following the completion of the sale, the insider now directly owns 147,435 shares in the company, valued at $5,949,002.25. The disclosure for this sale can be found here. Insiders sold 269,287 shares of company stock worth $11,034,960 over the last ninety days. 0.69% of the stock is currently owned by insiders.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.